Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 10/20 | 0.44 |
| ▸ | HTR2C | P28335 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97860 | 0.84 | PSEN1 (0.41) | DAOIDO1AGXT | |
| SCHEMBL6140760 | 0.81 | IDO1 (0.50) | DAOIDO1AGXTHTR2AHTR2C | |
| SCHEMBL7700904 | 0.80 | IDO1 (0.58) | DAOIDO1AGXTHTR2AHTR2C | |
| SCHEMBL4717377 | 0.80 | IDO1 (0.46) | DAOIDO1AGXTHTR2AHTR2C | |
| SCHEMBL10683292 | 0.77 | — | — | |
| SCHEMBL6142836 | 0.77 | IDO1 (0.50) | DAOIDO1AGXTHTR2AHTR2C | |
| SCHEMBL4837810 | 0.77 | HDAC1 (0.37) | MAOB | |
| SCHEMBL3582623 | 0.76 | IDO1 (0.46) | DAOIDO1AGXTHTR2AHTR2C | |
| SCHEMBL4847066 | 0.76 | RIPK1 (0.39) | — | |
| SCHEMBL5538107 | 0.75 | TAAR1 (0.56) | DAOIDO1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| EP-0796618-B1 | Treatment and prophylaxis of pancreatitis | SANKYO CO (JP) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000041690-A9 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | UNIV CALIFORNIA (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2000041690-A1 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5968960-A | ANTIISCHEMIC AGENTS AND HYPOTENSIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-10-19 | — | — | US | disclosed |
| US-5804590-A | ADMINISTERING DERIVATIVES OF THIAZOLIDINE; ANTI-DIABETIC AGENTS. | SANKYO COMPANY, LIMITED (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5753681-A | INSULIN SENSITIZERS | SANKYO COMPANY, LIMITED (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0783888-A1 | Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis | SANKYO COMPANY LIMITED (JP) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | DAO 611/4885IDO1 647/4885AGXT 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.